A report issued by the Senate Homeland Security and Governmental Affairs Committee Majority highlights the scale and ongoing nature of the drug shortage crisis in the U.S. But FDA watchers should keep an eye on something else: The potential for the report to act as a blueprint for future legislation.
Regulatory context: FDA’s statutory authorities for drug shortage mitigation
Drug shortages are a serious public health concern that reached a crisis level in the early 2010s.
Fill out the form to read the full article.